Cohort Studies Practice Test (Sample)

Study Guide

Everything you need from our exam experts!

Table of Contents

Introduction

Preparing for a certification exam can feel overwhelming, but with the right tools, it becomes an opportunity to build confidence, sharpen your skills, and move one step closer to your goals. At Examzify, we believe that effective exam preparation isn't just about memorization, it's about understanding the material, identifying knowledge gaps, and building the test-taking strategies that lead to success.

This guide was designed to help you do exactly that.

Whether you're preparing for a licensing exam, professional certification, or entry-level qualification, this book offers structured practice to reinforce key concepts. You'll find a wide range of multiple-choice questions, each followed by clear explanations to help you understand not just the right answer, but why it's correct.

The content in this guide is based on real-world exam objectives and aligned with the types of questions and topics commonly found on official tests. It's ideal for learners who want to:

- **Practice answering questions under realistic conditions,**
- **Improve accuracy and speed,**
- **Review explanations to strengthen weak areas, and**
- **Approach the exam with greater confidence.**

We recommend using this book not as a stand-alone study tool, but alongside other resources like flashcards, textbooks, or hands-on training. For best results, we recommend working through each question, reflecting on the explanation provided, and revisiting the topics that challenge you most.

Remember: successful test preparation isn't about getting every question right the first time, it's about learning from your mistakes and improving over time. Stay focused, trust the process, and know that every page you turn brings you closer to success.

Let's begin.

How to Use This Guide

This guide is designed to help you study more effectively and approach your exam with confidence. Whether you're reviewing for the first time or doing a final refresh, here’s how to get the most out of your Examzify study guide:

1. Start with a Diagnostic Review

Skim through the questions to get a sense of what you know and what you need to focus on. Your goal is to identify knowledge gaps early.

2. Study in Short, Focused Sessions

Break your study time into manageable blocks (e.g. 30 – 45 minutes). Review a handful of questions, reflect on the explanations.

3. Learn from the Explanations

After answering a question, always read the explanation, even if you got it right. It reinforces key points, corrects misunderstandings, and teaches subtle distinctions between similar answers.

4. Track Your Progress

Use bookmarks or notes (if reading digitally) to mark difficult questions. Revisit these regularly and track improvements over time.

5. Simulate the Real Exam

Once you're comfortable, try taking a full set of questions without pausing. Set a timer and simulate test-day conditions to build confidence and time management skills.

6. Repeat and Review

Don’t just study once, repetition builds retention. Re-attempt questions after a few days and revisit explanations to reinforce learning. Pair this guide with other Examzify tools like flashcards, and digital practice tests to strengthen your preparation across formats.

There’s no single right way to study, but consistent, thoughtful effort always wins. Use this guide flexibly, adapt the tips above to fit your pace and learning style. You've got this!

Questions

1. What does a cohort study typically compare?

A. Two or more groups defined by exposure status and followed over time to observe outcomes.

B. A group of individuals with the disease compared to those without.

C. A cross-sectional snapshot.

D. A randomized trial.

2. Which method assesses unmeasured confounding that could explain away an observed association?

A. E-value

B. Kaplan-Meier curve

C. Hazard ratio

D. Mann-Whitney test

3. What is the primary purpose of stratified analysis in detecting effect modification?

A. To estimate stratum-specific estimates of the exposure effect

B. To maximize overall pooled effect size

C. To avoid stratification altogether

D. To validate data with separate sample

4. What are competing risks and how do they affect cohort analyses?

A. They are rare events that can be ignored in most analyses

B. They increase the observed incidence of the primary outcome

C. They preclude the outcome and may bias standard analyses

D. They only affect exposure assessment

5. How can sensitivity analyses assess the potential impact of unmeasured confounding in a cohort study?

A. Using stratification by measured confounders only

B. Use the E-value to quantify how strong an unmeasured confounder would need to explain away the observed association

C. Increasing sample size

D. Collecting more outcome events

6. Distinguish open (dynamic) and closed (fixed) cohorts and discuss implications for analysis.

A. Open cohort has fixed membership and no new entrants; closed cohort does not.

B. Open cohort allows new entrants during follow-up and losses; they affect person-time calculation and exposure classification.

C. Closed cohort permits new entrants during follow-up but forbids losses.

D. Open cohorts do not permit exposure changes over time.

7. Outcome Types in cohort studies typically include which of the following?

A. Only mortality

B. Clinical events; lab markers; healthcare utilization

C. Genetic markers only

D. Patient satisfaction scores

8. What does transportability refer to in cohort studies?

A. Ability to apply findings to other populations or settings

B. Internal validity only

C. Statistical power

D. The speed of data collection

9. What is person-time and how is it used to compute incidence rate?

A. Person-time is the sum of follow-up time across all individuals at risk; incidence rate = new cases divided by total person-time.

B. Person-time is the number of people in the study; incidence rate = new cases divided by baseline population.

C. Person-time is the time at which the first case occurs.

D. Person-time is the time until the last participant is recruited.

10. Which statement is true about RR values for a negative outcome?

A. RR less than 1 indicates decreased risk in the exposed group.

B. RR greater than 1 indicates decreased risk.

C. RR equals 1 indicates increased risk.

D. RR cannot be interpreted.

Answers

1. A
2. A
3. A
4. C
5. B
6. B
7. B
8. A
9. A
10. A

Explanations

1. What does a cohort study typically compare?

A. Two or more groups defined by exposure status and followed over time to observe outcomes.

B. A group of individuals with the disease compared to those without.

C. A cross-sectional snapshot.

D. A randomized trial.

Cohort studies compare outcomes between groups defined by exposure status and follow them over time. This design starts with people who are exposed to a factor and those who are not, then tracks them to see who develops the outcome of interest. Because exposure is established first and outcomes are observed afterward, you can estimate incidence and relative risk and establish temporality between exposure and outcome. This differs from a cross-sectional snapshot, which looks at exposure and outcome at a single time point; from a case-control study, which starts with disease status and looks back for exposure; and from a randomized trial, which assigns exposure randomly.

2. Which method assesses unmeasured confounding that could explain away an observed association?

A. E-value

B. Kaplan-Meier curve

C. Hazard ratio

D. Mann-Whitney test

The method being tested is a sensitivity measure that tells you how strong an unmeasured confounder would have to be to explain away the observed association. The E-value does this by providing the minimum strength of association that an unknown confounder would need to have with both the exposure and the outcome to nullify the observed effect, under the usual study assumptions. It helps you gauge the robustness of findings in observational studies without having measured that confounder. This is not what a Kaplan-Meier curve does—that curve shows survival probabilities over time and doesn't quantify how much unmeasured confounding could bias results. It's also not the hazard ratio, which is a measure of effect size between groups but doesn't itself assess potential unmeasured confounding. And a Mann-Whitney test compares distributions between groups without addressing confounding at all. So the E-value is the tool that explicitly addresses how unmeasured confounding could influence the observed association. For intuition, if you observe a risk ratio of, say, 2.0, the E-value would be 2.0 + sqrt(2.0*(2.0-1)) ≈ 3.41. That means an unmeasured confounder would need to have a fairly strong association (risk ratio around 3.4) with both the exposure and the outcome to fully explain away the observed association. The larger the E-value, the more robust the finding is to potential unmeasured confounding.

3. What is the primary purpose of stratified analysis in detecting effect modification?

A. To estimate stratum-specific estimates of the exposure effect

B. To maximize overall pooled effect size

C. To avoid stratification altogether

D. To validate data with separate sample

Effect modification happens when the impact of an exposure on an outcome changes across levels of another variable. Stratified analysis tackles this by estimating the exposure effect within each level of that variable. By looking at these stratum-specific effects, you can see whether the association is consistent or varies between groups. If the estimates differ across strata, that indicates the effect is modified by the stratifying factor. This approach directly reveals how the exposure's impact changes in different subgroups, rather than producing one overall pooled effect. That's why the main purpose is to estimate stratum-specific estimates of the exposure effect. The other ideas—maximizing a single pooled effect, avoiding stratification, or using separate samples for validation—do not address detecting how the effect changes across subgroups.

4. What are competing risks and how do they affect cohort analyses?

A. They are rare events that can be ignored in most analyses

B. They increase the observed incidence of the primary outcome

C. They preclude the outcome and may bias standard analyses

D. They only affect exposure assessment

Competing risks are events that prevent the occurrence of the outcome you're studying. In a cohort, if someone experiences a competing event—like death from another cause, or another irreversible endpoint—they can no longer develop the primary outcome of interest. This matters because standard survival analyses treat competing events as if individuals could still experience the primary outcome later, effectively censoring them in a nonrandom way. That leads to biased estimates: the risk of the primary outcome can be misrepresented, often overestimated when using methods like Kaplan-Meier, and hazard ratios from traditional Cox models can mislead if the competing risk isn't properly accounted for. To handle this, analysts use methods designed for competing risks, such as the cumulative incidence function that directly incorporates competing events, or subdistribution hazard models (Fine-Gray) that provide interpretation of risk in the presence of competing risks. The key point is that competing risks preclude the outcome and can bias standard analyses if not properly addressed.

5. How can sensitivity analyses assess the potential impact of unmeasured confounding in a cohort study?

A. Using stratification by measured confounders only

B. Use the E-value to quantify how strong an unmeasured confounder would need to explain away the observed association

C. Increasing sample size

D. Collecting more outcome events

The main idea here is using sensitivity analyses to gauge how unmeasured confounding might affect the observed association. The E-value provides a concrete, quantitative way to do this: it tells you the minimum strength that an unmeasured confounder would need to have with both the exposure and the outcome to explain away the observed association after accounting for measured confounders. If you find a large E-value, it means you'd need a fairly strong, perhaps unlikely confounder to negate your result, suggesting the finding is fairly robust to unmeasured confounding. This makes the sensitivity analysis directly focused on potential hidden bias rather than just increasing precision or adjusting for known factors. Stratifying by measured confounders only addresses bias from known factors and doesn't quantify the impact of unmeasured ones. Increasing sample size or collecting more outcome events improves precision and statistical power but does not directly assess or quantify unmeasured confounding.

6. Distinguish open (dynamic) and closed (fixed) cohorts and discuss implications for analysis.

A. Open cohort has fixed membership and no new entrants; closed cohort does not.

B. Open cohort allows new entrants during follow-up and losses; they affect person-time calculation and exposure classification.

C. Closed cohort permits new entrants during follow-up but forbids losses.

D. Open cohorts do not permit exposure changes over time.

The main idea being tested is how cohort membership changes over time and how that affects analysis. In an open (dynamic) cohort, people can enter the study at different times during follow-up and can also leave or be lost to follow-up. Because of this, the amount of time each person contributes to the study—person-time—varies and needs to be tracked from each individual's entry to their exit. Exposure status and other covariates may also change over time, so analyses must account for time-varying information, often using methods that handle time-dependent covariates (like time-dependent Cox models or Poisson models with person-time data). This is why the statement describing an open cohort as allowing new entrants during follow-up and losses, and noting that these dynamics affect both person-time calculation and exposure classification, is the best fit. It directly captures the essential implications for analysis. The other descriptions don't fit because they describe fixed membership, or they misstate which features belong to open versus closed cohorts, or they imply exposure cannot change over time. In a fixed (closed) cohort, membership is set at baseline with no new entrants, and losses occur only through censoring or death, making person-time and exposure often simpler to handle. In an open cohort, exposure and membership are dynamic, which is the key difference and driving factor for the appropriate analytic approach.

7. Outcome Types in cohort studies typically include which of the following?

A. Only mortality

B. Clinical events; lab markers; healthcare utilization

C. Genetic markers only

D. Patient satisfaction scores

In cohort studies, outcomes are the various events or measurements you follow people over time to observe. A well-designed cohort often looks at a broad mix of outcomes to capture both health events and underlying biology, giving a fuller picture of how an exposure affects people. That's why the best answer includes clinical events, laboratory markers, and healthcare utilization. You might track new diagnoses or complications (clinical events), changes in lab values that reflect biological processes (lab markers), and patterns like hospital visits or admissions (healthcare utilization). Together these provide a comprehensive view of impact over time. Focusing on mortality alone is too narrow because many studies examine more than just death, including nonfatal events and biological changes. Genetic markers by themselves aren't typical outcomes; they're often exposures or predictors, or used alongside outcomes. Patient satisfaction scores can be outcomes in some contexts but are not representative of the standard range of outcomes typically used in cohort research.

8. What does transportability refer to in cohort studies?

A. Ability to apply findings to other populations or settings

B. Internal validity only

C. Statistical power

D. The speed of data collection

Transportability refers to whether the findings from a cohort study can be applied to populations or settings beyond the one studied. This is about external validity or generalizability—can the observed association hold in a different group with different characteristics or in a different context? It's not about internal validity, which deals with biases within the study itself, nor about statistical power, which concerns the ability to detect an effect given the sample size, nor about how quickly data were collected. In practice, transportability considers whether differences in age, risk factors, or context might change the effect, and it often involves clearly describing the study population and setting and, when possible, validating findings in other groups or using methods that estimate what would happen in a target population.

9. What is person-time and how is it used to compute incidence rate?

A. Person-time is the sum of follow-up time across all individuals at risk; incidence rate = new cases divided by total person-time.

B. Person-time is the number of people in the study; incidence rate = new cases divided by baseline population.

C. Person-time is the time at which the first case occurs.

D. Person-time is the time until the last participant is recruited.

The key idea is that incidence rate uses person-time to account for how long people are actually at risk and under observation. Person-time is the total amount of time all individuals contribute while they are at risk and being followed. Each person contributes time until they develop the disease, are lost to follow-up, die, or the study ends. The incidence rate is then the number of new cases divided by the total person-time, giving a rate such as cases per person-year. This approach is especially useful when people enter the study at different times or are followed for different lengths of time, because it standardizes the risk across varying follow-up durations. For example, if you watch several people for different lengths of time and count how many develop the disease, you divide the number of new cases by the sum of everyone's observation time to get the rate. Other interpretations mix up counts with time: it's not just the number of people, not the baseline population, not the time to the first case, and not the time until the last participant is recruited. Those ideas don't capture the idea that each person's contribution to the denominator is the time they were actually at risk and observed.

10. Which statement is true about RR values for a negative outcome?

A. RR less than 1 indicates decreased risk in the exposed group.

B. RR greater than 1 indicates decreased risk.

C. RR equals 1 indicates increased risk.

D. RR cannot be interpreted.

Relative risk compares how likely the adverse outcome is in those exposed to a factor versus those not exposed. When the outcome is negative, a value below 1 means the exposure lowers the risk of that adverse outcome. For example, if the exposed group has a 5% risk and the unexposed group has a 10% risk, the RR is 0.5, showing decreased risk with exposure. If RR is greater than 1, the exposure increases risk; if RR equals 1, there is no difference in risk between groups. Therefore, the statement that RR less than 1 indicates decreased risk in the exposed group is true.

Next Steps

Congratulations on reaching the final section of this guide. You've taken a meaningful step toward passing your certification exam and advancing your career.

As you continue preparing, remember that consistent practice, review, and self-reflection are key to success. Make time to revisit difficult topics, simulate exam conditions, and track your progress along the way.

If you need help, have suggestions, or want to share feedback, we'd love to hear from you. Reach out to our team at hello@examzify.com.

Or visit your dedicated course page for more study tools and resources:

https://cohortstudies.examzify.com

We wish you the very best on your exam journey. You've got this!